Hematology

Delayed pegaspargase reduces hepatotoxicity without affecting outcomes.

Real-world data support momelotinib as an effective and well-tolerated treatment for myelofibrosis-related anemia.

Undetectable minimal residual disease rates improved with ongoing therapy.

Current treatment strategies are aimed at reducing hematocrit and symptom burden through phlebotomy, aspirin, and cytoreductive agents, while emerging therapies offer promise for better disease control and quality of life.

Mark Zangardi, PharmD, MS, BCOP, and Amber Cipriani, PharmD, BCOP, discuss the growing role of circulating tumor DNA (ctDNA) testing in oncology, highlighting its applications in early cancer detection, molecular residual disease assessment, and treatment monitoring.

Matthew Lei, PharmD, BCOP, highlights the value of community, collaboration, and innovation at the HOPA Annual Conference.

The multiple myeloma landscape is evolving, with bispecific T-cell engagers offering hope.

The trial showed that adding pelabresib to ruxolitinib improved outcomes in myelofibrosis with manageable side effects.

CAV-1 is a key protein in lipid rafts that helps control cellular processes such as growth, survival, and migration.

Siremadlin is a novel, investigational, second-generation antagonist that binds to MDM2.

Real-time profiling of T-cell activation states in non-CAR T-cells may help guide treatment decisions.

Pharmacists performed weekly toxicity and tumor lysis syndrome monitoring.

Patients with chronic lymphocytic leukemia (CLL) show weakened T-cell memory responses to COVID-19 vaccination.

Using Janus kinase inhibitors, having experienced a previous thrombosis episode, and higher age were associated with a heightened risk of a new thromboembolic event.

Adding daratumumab improved minimal residual disease (MRD) negativity rates, leading to superior progression-free survival (PFS).

Patients with central nervous system (CNS) involvement achieved favorable outcomes with chimeric antigen receptor (CAR) T-cell therapy.

Reducing the dose of ibrutinib following adverse events improved tolerability without compromising clinical efficacy in chronic lymphocytic leukemia (CLL).

A phase 2 study showed that elotuzumab combined with pomalidomide, bortezomib, and dexamethasone was safe and efficacious.

Lipid metabolism plays a critical role in the function of T-cells.

Approximately 10% of patients with multiple myeloma have pathogenic germline variants, indicating a hereditary risk.

Use of dexamethasone over tocilizumab was associated with significant cost-savings for patients with relapsed/refractory multiple myeloma (RRMM).

The favorable outcomes were observed in the phase 3 AMPLIFY trial.

The data supports quadruplet therapy’s potential in the first line for patients with newly diagnosed multiple myeloma (NDMM).

Risk stratification remains a challenge when selecting patients for treatment of smoldering multiple myeloma.

Pharmacists play a crucial role in medication management for these complex patients.

The drug solidifies its place as a first-line treatment option in AML.

BRAF V600E inhibitors show improved outcomes in relapsed/refractory hairy cell leukemia.

C. Brooke Adams, PharmD, BCOP, discusses the evolving diagnostic criteria and management strategies for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in CAR T-cell therapy, highlighting advances in toxicity prevention and treatment selection.

OPN-6602 is an oral EP300/CBP bromodomain inhibitor that yielded 100% tumor regression as a combination therapy in mouse models.

Diversity in clinical trials remains important to ensure research data for therapies accurately reflects the diverse patient populations who will use them globally.